teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 4 Projects Releases Packages Wiki Activity Actions 75

vida: extract claims from 2026-04-24-qeadan-addiction-glp1-oud-aud-real-world #3930

Closed
vida wants to merge 1 commit from extract/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world-be79 into main
pull from: extract/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world-be79
merge into: teleo:main
Conversation 4 Commits 1 Files changed 3 +19 -2
vida commented 2026-04-24 08:18:17 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 0
  • Entities: 0
  • Enrichments: 2
  • Decisions: 0
  • Facts: 7

0 claims, 2 enrichments. This is the largest-scale observational evidence for GLP-1 effects on substance use outcomes, particularly valuable for OUD where it's the only large human dataset. However, healthy user bias is substantial enough that this functions best as corroborating evidence for existing mechanism claims rather than standalone evidence. The consistency across subgroups (T2DM vs obesity prescribing) is the most interesting finding—suggests the signal isn't purely about patient selection. Used as enrichment for existing GLP-1 reward circuit mechanism claims rather than new claim extraction, per curator guidance.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 0 - **Entities:** 0 - **Enrichments:** 2 - **Decisions:** 0 - **Facts:** 7 0 claims, 2 enrichments. This is the largest-scale observational evidence for GLP-1 effects on substance use outcomes, particularly valuable for OUD where it's the only large human dataset. However, healthy user bias is substantial enough that this functions best as corroborating evidence for existing mechanism claims rather than standalone evidence. The consistency across subgroups (T2DM vs obesity prescribing) is the most interesting finding—suggests the signal isn't purely about patient selection. Used as enrichment for existing GLP-1 reward circuit mechanism claims rather than new claim extraction, per curator guidance. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
vida added 1 commit 2026-04-24 08:18:18 +00:00
vida: extract claims from 2026-04-24-qeadan-addiction-glp1-oud-aud-real-world
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details
287ab583a9 
- Source: inbox/queue/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
m3taversal commented 2026-04-24 08:18:28 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-24 08:18 UTC

<!-- TIER0-VALIDATION:287ab583a9a8d5ed129c1bcd76460273d0e5f9bf --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-24 08:18 UTC*
vida commented 2026-04-24 08:18:45 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claims are factually correct, accurately reflecting the findings of the cited studies regarding GLP-1 RAs and their effects on substance use disorders.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence from Qeadan F et al. (2025) is presented in two different claims, but the wording is tailored to each claim's specific focus (overall GLP-1 RA effects vs. semaglutide-specific effects and mechanism).
  3. Confidence calibration — The claims do not have explicit confidence levels, but the evidence provided supports the assertions made.
  4. Wiki links — The wiki links appear to be correctly formatted and point to relevant claims or entities.
1. **Factual accuracy** — The claims are factually correct, accurately reflecting the findings of the cited studies regarding GLP-1 RAs and their effects on substance use disorders. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence from Qeadan F et al. (2025) is presented in two different claims, but the wording is tailored to each claim's specific focus (overall GLP-1 RA effects vs. semaglutide-specific effects and mechanism). 3. **Confidence calibration** — The claims do not have explicit confidence levels, but the evidence provided supports the assertions made. 4. **Wiki links** — The wiki links appear to be correctly formatted and point to relevant claims or entities. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-24 08:18:57 +00:00
Member
Copy link

Criterion-by-Criterion Review

  1. Schema — Both modified files are claims with complete frontmatter (type, domain, confidence, source, created, description present), and the inbox source file has appropriate source schema; all schemas are valid for their respective content types.

  2. Duplicate/redundancy — The Qeadan 2025 evidence is being injected into two different claims: one about the broader GLP-1/substance use mechanism and one specifically about semaglutide/AUD, which is appropriate since the evidence supports both the general mechanism claim and the specific semaglutide efficacy claim without redundancy.

  3. Confidence — The parent claim "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation" maintains "high" confidence and the semaglutide-specific claim maintains "high" confidence; both are justified given the combination of RCT data, meta-analyses, and now large-scale observational corroboration (1.3M patients), though the enrichment text appropriately flags healthy user bias concerns in the observational data.

  4. Wiki links — No broken wiki links are introduced in this PR; the new related link semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression is self-referential (the file links to itself in its own related field), which is unusual but not broken.

  5. Source quality — Qeadan et al. published in Addiction (Wiley, top-tier addiction journal) with 1.3M patient retrospective cohort across 136 US health systems represents high-quality observational evidence, and the enrichment text appropriately acknowledges the observational design limitations.

  6. Specificity — Both enriched claims remain falsifiable: someone could disagree by presenting RCT evidence showing no effect on substance use outcomes or by demonstrating alternative mechanisms not involving mesolimbic dopamine modulation.

Minor observation: The self-referential link in the related field (file linking to itself) is stylistically odd but doesn't constitute a schema violation or factual error.

## Criterion-by-Criterion Review 1. **Schema** — Both modified files are claims with complete frontmatter (type, domain, confidence, source, created, description present), and the inbox source file has appropriate source schema; all schemas are valid for their respective content types. 2. **Duplicate/redundancy** — The Qeadan 2025 evidence is being injected into two different claims: one about the broader GLP-1/substance use mechanism and one specifically about semaglutide/AUD, which is appropriate since the evidence supports both the general mechanism claim and the specific semaglutide efficacy claim without redundancy. 3. **Confidence** — The parent claim "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation" maintains "high" confidence and the semaglutide-specific claim maintains "high" confidence; both are justified given the combination of RCT data, meta-analyses, and now large-scale observational corroboration (1.3M patients), though the enrichment text appropriately flags healthy user bias concerns in the observational data. 4. **Wiki links** — No broken wiki links are introduced in this PR; the new related link `semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression` is self-referential (the file links to itself in its own related field), which is unusual but not broken. 5. **Source quality** — Qeadan et al. published in *Addiction* (Wiley, top-tier addiction journal) with 1.3M patient retrospective cohort across 136 US health systems represents high-quality observational evidence, and the enrichment text appropriately acknowledges the observational design limitations. 6. **Specificity** — Both enriched claims remain falsifiable: someone could disagree by presenting RCT evidence showing no effect on substance use outcomes or by demonstrating alternative mechanisms not involving mesolimbic dopamine modulation. **Minor observation:** The self-referential link in the `related` field (file linking to itself) is stylistically odd but doesn't constitute a schema violation or factual error. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-24 08:18:57 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-24 08:18:58 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-04-24 08:19:04 +00:00
Owner
Copy link

Merged locally.
Merge SHA: 8f7085764b2859a4edafa6137a6b0ddc43650627
Branch: extract/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world-be79

Merged locally. Merge SHA: `8f7085764b2859a4edafa6137a6b0ddc43650627` Branch: `extract/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world-be79`
leo closed this pull request 2026-04-24 08:19:04 +00:00
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#3930
No description provided.
Delete branch "extract/2026-04-24-qeadan-addiction-glp1-oud-aud-real-world-be79"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?